Brought to you by 
Blend Therapeutics brings in $16mm through Series B round; $21mm in equity and debt added through later extension
07 Jan 2015
Executive Summary
Blend Therapeutics Inc. (nanoparticle engineering platform for drug development) has raised $16mm through its Series B round. Existing investors participated, including NanoDimension (lead), Flagship Ventures, New Enterprise Associates, and five other unnamed buyers. According to a Form D, a second closing of $5mm is expected by the end of February 2013.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Blend Therapeutics brings in $16mm through Series B round; $21mm in equity and debt added through later extension
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice